Want to see INSM full AI Analyst Report?
INSM Stock Chart & Stats
$144.48
-$1.02(-1.54%)
At close: 4:00 PM EST
$144.48
-$1.02(-1.54%)
Day’s Range― - ―
52-Week Range$90.39 - $212.75
Previous CloseN/A
Volume462.72K
Average Volume (3M)4.14M
Market Cap
$23.48B
Enterprise Value$34.76K
Total Cash (Recent Filing)$1.22B
Total Debt (Recent Filing)$748.43M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Jul 30, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.75
Shares Outstanding216,752,460
10 Day Avg. Volume2,438,720
30 Day Avg. Volume4,141,554
Financial Highlights & Ratios
PEG Ratio-1.80
Price to Book (P/B)50.31
Price to Sales (P/S)61.31
P/FCF Ratio-38.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$198.82Price Target Upside37.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.62
Revenue Forecast (FY)$1.70B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsSustained top-line momentum (TTM revenue +35.1%) combined with very high gross margins (~76%–82%) provide a durable revenue and margin base. This supports scalable gross profit as launches ramp, enabling future operating leverage if SG&A/R&D growth is curtailed.
BRINSUPRI Commercial ExecutionStrong launch metrics—44% sequential growth, fast payer approvals (~90%), >5,000 prescribers, >80% patient support enrollment and ~30‑day refill cadence—indicate durable adoption, reimbursement acceptance and patient retention that underpin predictable recurring product revenue.
Stronger Balance Sheet And Cash RunwayA meaningful reduction in debt to ~$38M, positive equity and ~ $1.2B in cash offer a multi-quarter runway to fund commercialization and late‑stage TPIP trials. Low leverage (debt/equity ~0.05) reduces refinancing risk and gives management flexibility to execute strategic plans.
Bears Say
Severe Negative Cash FlowVery large operating and free cash outflows signal material burn relative to current revenue. Until the company achieves sustained cash-flow positivity, it remains dependent on execution, expense control or external financing, creating structural funding risk if revenue ramps slower than assumed.
Persistent Operating LossesDespite high gross margins, operating expenses far exceed gross profit, producing deep operating and net losses. Structural profitability requires sustained revenue scale or marked cost reduction; absent that, returns on capital remain negative and value creation is delayed.
Policy, Payer And Competitive RiskUncertainty from U.S. MFN policy and potential future payer tightening can materially delay or restrict international expansion and compress reimbursement. Combined with competing treprostinil programs, these structural access and competitive pressures could limit market share and pricing power over time.
Insmed News
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $90.39 and its highest was $212.75 in the past 12 months.
What is Insmed’s market cap?
Insmed’s market cap is $23.48B.
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on May 07, 2026. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.963 by $0.203.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -0.7.
How many shares outstanding does Insmed have?
Insmed has 216,752,460 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.963. Following the earnings report the stock price went down -23.408%.
Which hedge fund is a major shareholder of Insmed?
Currently, no hedge funds are holding shares in INSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$198.82 (37.61% Upside)
$198.82 (37.61% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 749.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.15%
Trailing 12-Months
Company Description
Insmed
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
INSM Stock 12 Month Forecast
Average Price Target
$198.82
▲(37.61% Upside)
Technical Analysis
Ownership Overview
0.72% Insiders
31.64% Mutual Funds
0.27% Other Institutional Investors
51.14% Public Companies and
Individual Investors